Displaying articles by keyword ETAR

ISSN 2304-7232

Artificial heart creation: what problems are to be solved?

Attempts to create an artificial heart were highlighted by our journal one year ago. Now we can say that there…

Occurrence of HLA- and non-HLA antibodies after heart transplantation…

Cardiac allograft vasculopathy (CAV) accounts for major morbidity and mortality late in the heart transplant (HTx) history. The role of…

Spotlight on management of hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the commonest inherited cardio-myopathy. Prevalence 1/500 individuals. The disease has variable expressivity and penetrance, which leads…

Study of effects of simulated space flight factors and…

The article considers the development of the periodic table of ECG phase changes which should reflect the variety of the…

Identification of non-HLA antibodies in ventricular assist device recipients

Published in No.3 November 2013

Recipients of ventricular assist devices (VADR) have a higher incidence to develop antibodies (Abs) against human leukocyte antigens (HLA). Non-HLA antibodies like major histocompatibility complex class I-related chain A (MICA) and autoantibodies against angiotensin type 1 receptor (AT1R) and endothelin receptor A (ETAR) are also implicated in the pathogenesis of acute rejection and allograft vasculopathy. We monitored non-HLA- and HLA-Abs in VADR up to one year after implantation.